Skip to main content
. 2019 Nov 9;18:146. doi: 10.1186/s12933-019-0954-6

Fig. 7.

Fig. 7

Effects of liraglutide on ERK1/2 pathway in HepG2 cells with or without high glucose. Liraglutide increased p-ERK1/2 protein expression in HepG2 cells in a time-dependent manner (a). U0126, the ERK1/2 inhibitor, attenuated the increased ABCA1 expression induced by liraglutide in HepG2 cells (b). Under high glucose (HG, 50 mM) condition, U0126 reduced the increased ABCA1 expression induced by liraglutide in HepG2 cells (c). *p < 0.05, **p < 0.01,***p < 0.001, ****p < 0.0001 vs control group